Current Trends in GLP-1 Clinical Trials

May 21, 2025

For many who grapple with the complexities of weight management, the journey can often feel like a cycle of fleeting hope. However, a promising new class of therapies is emerging: GLP-1 receptor agonists. Initially developed for diabetes, these drugs are now at the forefront of a revolution in obesity treatment.

This shift is backed not only by promising science findings but also by the market's explosive growth, projected to hit $173.5 billion by 2031. GLP-1 clinical trials are underway, shaping a future where effective weight management may become more accessible.

In this blog, we will explore the current trends in these trials, focusing on innovative approaches for obesity and the crucial aspect of patient compliance.

Join us as you discover the exciting possibilities of GLP-1-based therapies beyond weight loss.

Understanding GLP-1 drugs

Glucagon-like peptide-1, or GLP-1, is a naturally occurring incretin hormone produced in the gut. It plays a vital role in several key physiological processes, including regulating blood sugar levels, slowing gastric emptying, and promoting a sense of fullness. This makes GLP-1 an integral part of managing diabetes and obesity.

Due to these benefits, scientists initially developed medications that mimicked the actions of natural GLP-1 for more effective treatments for type 2 diabetes. These drugs, known as GLP-1 receptor agonists (GLP-1 RAs), work by stimulating insulin release when glucose rises and suppressing the secretion of glucagon, another hormone that raises blood sugar.

Unlike several diabetes medications, GLP-1 receptor agonists are unique because they only boost insulin secretion when blood glucose is high, minimising the danger of hypoglycemia. This glucose-dependent activation distinguishes them as safer alternatives.

The role of GLP-1 in obesity treatment

As these GLP-1 RAs were being used in clinical trials for diabetes, an intriguing and significant secondary effect became apparent: Weight loss.

This observation addressed a significant unmet need, as many individuals with type 2 diabetes are also overweight or obese, and effective weight management is crucial for their overall health. The ability of GLP-1 RAs to promote satiety and slow gastric emptying contributed to this weight-reducing effect, paving the way for their exploration as dedicated obesity treatments.

Also read: Do GLP-1 Supplements Work Naturally for Health

Key GLP-1 medications

Here are some prominent GLP-1 receptor agonists available today:

Semaglutide (Ozempic, Wegovy, Rybelsus): Known for its remarkable weight loss outcomes, it significantly improved over past GLP-1 receptor agonists.
Tirzepatide (Mounjaro, Zepbound): Provides a dual mechanism targeting both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. It shows greater glucose control and weight reduction efficacy than GLP-1 RAs alone.
Liraglutide (Saxenda): An earlier GLP-1 receptor agonist that set the stage for current advancements.
Dulaglutide (Trulicity): Primarily used for managing type 2 diabetes, it is also being studied for its effects on weight and cardiovascular outcomes.
Exenatide (Byetta, Bydureon): Another earlier generation GLP-1 RA widely recognised for its efficacy in managing glucose levels.

Learn how The Good Bug maximised your gut’s ability to promote GLP-1 production by developing the Supercharged Metabolically Lean probiotic. Watch the video below to gain expert insights.

Curious to see how these impressive drugs actually work for obesity? Let's break down the science of GLP-1 and its impacts.

GLP-1 clinical trials for obesity

The primary objective of GLP-1 clinical trials is to rigorously evaluate the efficacy and safety of these medications in promoting significant and sustainable weight loss in individuals with overweight or obesity. These trials aim to determine the optimal use of GLP-1 RAs as a therapeutic intervention, often in conjunction with lifestyle modifications such as diet and exercise.

Focus on efficacy and dosage optimisation

A significant area of research involves exploring higher doses of already approved GLP-1 RAs like semaglutide and liraglutide to push beyond current weight loss thresholds:

Higher dose investigations: Ongoing studies suggest these increased doses could yield greater weight reductions, although careful dose titration is necessary to manage side effects.
Head-to-head comparisons: To understand which GLP-1 RA might be most effective for specific patient profiles, clinical trials directly compare the efficacy of different drugs within this class in obese populations.
Personalised dosing strategies: As interest in personalised medicine grows, trials also examine how individual dosing adjustments might enhance patient outcomes based on their unique responses and tolerability.

Also read: How to Naturally Increase GLP-1 Levels?

Addressing patient compliance and convenience

Improving patient compliance and convenience is another critical focal point.

Oral formulation: Many trials are testing novel administration routes, including oral formulations of GLP-1 agents such as oral semaglutide, which could improve patient preference and adherence compared to injectable medications.
Longer-acting injectables: To simplify treatment regimens and improve adherence rates, longer-acting injectable formulations that require administration once monthly or even less frequently are being developed.
Digital health and support programs: Clinical trials are also exploring integrating digital health tools (e.g., smartphone apps, wearable devices) and patient support programs to improve adherence to GLP-1 therapy and lifestyle modifications.

Combination therapies for enhanced outcomes

The concept of combining GLP-1 RAs with other weight loss drugs is gaining momentum. These combination strategies target multiple aspects of appetite regulation and energy expenditure simultaneously. By acting on different pathways, these combinations may lead to more substantial and sustained weight loss than monotherapy with a GLP-1 RA alone.

Examples include amylin analogues and selective melanocortin-4 receptor agonists. Clinical trials are underway to assess the safety and efficacy of these combination therapies in achieving greater weight loss and improving metabolic parameters.

Focus on specific patient subgroups

Recognising the heterogeneity of the obese population, numerous clinical trials are specifically examining the efficacy and safety of GLP-1 RAs on specific patient subgroups:

Obesity with comorbidities, like cardiovascular diseases or non-alcoholic steatohepatitis (NASH), and kidney disease. These studies aim to determine if GLP-1 RAs offer additional benefits beyond weight loss in these populations.
Biomarker identification: Researchers are also working to identify biomarkers (e.g., genetic markers, specific protein levels) that could predict an individual's response to GLP-1 therapy. This precision medicine approach aims to personalise treatment decisions, ensuring that they meet the needs of a broader patient demographic.

Feeling inspired yet? Let's explore the broader possibilities these drugs hold beyond obesity.

Therapeutic potential of GLP-1 beyond obesity

The scope of GLP-1 receptor agonists has expanded remarkably, revealing potential benefits that stretch beyond their well-known use in treating type 2 diabetes and obesity. These versatile medications offer therapeutic promise in various conditions, underscoring their potential to address multiple health challenges:

NASH (Non-alcoholic Steatohepatitis): Clinical trials are revealing that GLP-1 RAs may hold promise in reducing liver fat and inflammation, potentially slowing the progression of NASH, a serious liver condition.
Cardiovascular disease: Large-scale trials are underway to explore the long-term cardiovascular benefits of GLP-1 RAs in a broader spectrum of patients, including those without diabetes but with existing cardiovascular risk factors.
Neurodegenerative diseases: Early-stage research suggests that GLP-1 RAs may possess neuroprotective properties, potentially offering new therapeutic strategies for debilitating conditions like Alzheimer's and Parkinson's disease.
Other potential applications: Investigations are also exploring the role of GLP-1 RAs in other areas, including kidney disease, women’s health (specifically polycystic ovarian syndrome - PCOS), and various gastrointestinal disorders.

But with every breakthrough comes challenges. Let’s examine the hurdles researchers face while uncovering GLP-1's full potential.

Challenges in GLP-1 clinical trials

The rapid advancements and promising results in GLP-1 clinical trials are not without their hurdles. As researchers around the globe strive to unlock the full potential of these therapies, several key challenges need careful consideration to ensure successful development and equitable access.

Here are some of the critical challenges being addressed in ongoing GLP-1 clinical trials:

Patient compliance due to side effects and injectable forms

The most commonly reported side effects of GLP-1 RAs are gastrointestinal issues like nausea, vomiting, and diarrhoea. These issues are aggravated by the need for frequent injections, which can deter prolonged use and impact patient comfort and adherence to the study protocol.

Clinical trials are actively working to mitigate these issues through various strategies:

Implementing slower titration schedules allows patients more time to adjust to the medication.
Developing formulations with potentially better tolerability profiles, aiming for smoother and gentler action.
Investigating the use of anti-nausea medications as adjunct therapy to manage these side effects effectively.
Prioritising the development of less frequent injectable options (e.g., monthly) and convenient oral formulations to improve long-term compliance.

Global shortage and accessibility

The increasing demand for GLP-1 therapies, particularly for weight management, has led to global supply challenges. This shortage can directly affect patient access to clinical trials and delay study timelines.

To address this long-term, clinical trials are exploring more cost-effective manufacturing processes and investigating alternative delivery systems. This makes drugs easier and less expensive to produce and distribute, ultimately aiming to improve global accessibility.

Ethical considerations

The use of potent weight loss drugs like GLP-1 RAs raises several critical ethical considerations. These are being carefully covered in clinical trial design and execution:

Addressing the potential for weight stigma and ensuring that these medications are viewed as medical treatments rather than lifestyle solutions.
Understanding the importance of continuity of care for patients who experience significant benefits during the trial period and planning for post-trial access to treatment.
Ensuring the necessity of comprehensive informed consent that clearly outlines the potential benefits, risks, and long-term implications of participating in the study.
Actively working towards ensuring equitable access to these potentially life-changing therapies and avoiding the worsening of existing health disparities based on socioeconomic status or geographic location.
Thoroughly evaluating the treatment's long-term safety and sustainability with GLP-1 RAs over many years.
Carefully defining appropriate treatment duration and patient selection criteria in clinical trials ensures that the right individuals are included and receive the most benefit.

Also read: Slow Metabolism: Common Weight Loss Mistakes to Avoid

Now, it's time to envision what's next. Let’s take a peek into the future of GLP-1 research.

Future directions in GLP-1 clinical research

The field of GLP-1 therapeutics is characterised by a relentless pursuit of improvement and expansion. Future clinical research is focused on innovative approaches to tackle existing challenges and unlock even greater potential for these groundbreaking medications.

Here are some key futuristic directions shaping GLP-1 clinical research:

Next-generation GLP-1 analogues and co-agonists

The development pipeline is rich with novel GLP-1 analogues engineered for potentially enhanced weight loss and glucose control efficacy, coupled with improved tolerability profiles to minimise gastrointestinal side effects.

Significant progress is being made in dual and even triple receptor agonists, such as those targeting GLP-1, GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors. Early clinical trial results have demonstrated remarkable promise in achieving even greater weight loss and superior metabolic control than GLP-1 RAs alone.

A phase 2 clinical trial involving 338 obese adults demonstrated the significant potential of retatrutide, a novel unimolecular triple agonist. At 48 weeks, participants who received the highest dose of retatrutide (12 mg) experienced an average weight loss of 24.2%, substantially greater than the 2.1% weight loss in the placebo group.

Also read: Effective Ways to Lose Belly Fat Fast

Oral and alternative delivery systems

A strong emphasis remains on developing convenient oral GLP-1 formulations that can significantly improve patient preference and long-term adherence, eliminating the need for injections.

Researchers are also exploring alternative delivery methods beyond subcutaneous injections, such as nasal sprays and implantable devices designed for sustained and controlled release of GLP-1 agonists over extended periods.

Precision medicine approaches

Precision medicine approaches promise a future where GLP-1 therapies are customised to genetic or biomarker profiles, enabling healthcare providers to predict and optimise individual treatment responses. This personalisation could be transformative, ensuring maximum efficacy with minimised side effects tailored to the patient's unique biology.

Long-term outcome studies

Crucial long-term clinical trials are ongoing to assess the sustained efficacy and safety of GLP-1 receptor agonists over many years. These studies are particularly focused on evaluating their impact on major cardiovascular events (like heart attack and stroke) and long-term metabolic outcomes (such as the prevention or progression of type 2 diabetes and related complications).

Focus on earlier intervention

With preventative medicine in focus, future research is exploring the use of GLP-1 therapies for earlier intervention in individuals identified as being at high risk, such as those with pre-diabetes or in the early stages of obesity. The goal is to determine if GLP-1 RAs can help prevent the progression to more severe metabolic diseases and improve long-term health outcomes.

Also read: Best Lean Protein Foods for Weight Loss

The trajectory of GLP-1 clinical trials paints an optimistic picture for the future of metabolic health. While not a singular solution, these innovative therapies fundamentally change how we approach obesity and its related conditions.

Staying informed about these rapid advancements is key. If you’re struggling with the complexities of weight management or related metabolic issues, consult a healthcare professional to understand the potential role of GLP-1 therapies.

Do you wish to chart a course towards better health? Start with The Good Bug’s probiotics and prebiotics, which target gut health and overall wellness. Visit our website to explore our products and resources, and take charge of your well-being!